Clearmind Medicine Inc. (CMND)
About Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $2.4M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $2.4M
- Shares outstanding
- 2.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 10, 2021
Clearmind Medicine Inc. (CMND) Stock Price
- Trading 100% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Clearmind Medicine Inc..
Write a review
News about Clearmind Medicine Inc.
News & sentiment via Polygon.io
Clearmind Medicine Inc.: frequently asked questions
Is Clearmind Medicine Inc. an American company?
Clearmind Medicine Inc. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Clearmind Medicine Inc. publicly traded?
Yes — Clearmind Medicine Inc. is a publicly traded company. Its stock trades under the ticker symbol CMND on the NASDAQ.
What does Clearmind Medicine Inc. do?
Clearmind Medicine Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
